Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral MS Therapies Move Closer, But Still Far From Approval And Adoption

Executive Summary

The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers

You may also be interested in...



Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market

FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.

Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market

FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.

Follow-on Biologic's Day Will Come - Post 2015, Teva Says

The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.

Related Content

Topics

UsernamePublicRestriction

Register

OM016808

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel